Roswell Park-Led Study Shows Promise for New Targeted Combination in People With Relapsed AML - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Roswell Park-Led Study Shows Promise for New Targeted Combination in People With Relapsed AML

New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational treatment approach using the targeted therapy ziftomenib for patients with a difficult-to-treat form of acute myeloid leukemia (AML).

  • By

  • August 26, 2026

  • 3 min

Share

  • 1

    A study led by Dr. Eunice Wang at Roswell Park evaluated a three-drug combination therapy for relapsed acute myeloid leukemia (AML).

  • 2

    The combination therapy included ziftomenib, venetoclax, and azacitidine, showing nearly 90% response in previously untreated patients.

  • 3

    Among previously untreated patients, 70% achieved complete or near-complete remission, with many responses being deep and durable.

  • 4

    The treatment was well tolerated, with low rates of serious side effects, and responses occurred quickly, within about four weeks.

  • 5

    Ziftomenib is currently approved as a single agent for relapsed AML, but its combination use remains investigational.

Original Source(s)

Roswell Park-Led Study Shows Promise for New Targeted Combination in People With Relapsed AML

  • by

  • August 26, 2026

Related Content

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

Anatomical site and histological subtype as determinants of Breslow thickness and high-risk features in surgically managed cutaneous melanoma at Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa

Author Correction: Low-protein diet enhances antitumor immunity in pancreatic cancer through microbiota-derived UDP-galactose